CC BY 4.0 · TH Open 2021; 05(03): e319-e328
DOI: 10.1055/s-0041-1729171
Original Article

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores

Ramón Lecumberri
1   Hematology Service, Clínica Universidad de Navarra, IdISNA, Pamplona; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain
,
Laura Jiménez
2   Deparment of Internal Medicine, Hospital Virgen de la Luz, Cuenca, Spain
,
Pedro Ruiz-Artacho
3   Deparment of Internal Medicine, Interdisciplinar Teragnosis and Radiosomics Research Group (INTRA-Madrid), Instituto de Salud Carlos III, University of Navarra, Clínica Universidad de Navarra, CIBERES, Madrid, Spain
,
José Antonio Nieto
2   Deparment of Internal Medicine, Hospital Virgen de la Luz, Cuenca, Spain
,
Nuria Ruiz-Giménez
4   Department of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain
,
Adriana Visonà
5   Department of Vascular Medicine, Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy
,
Andris Skride
6   Department of Cardiology, Ospedale Pauls Stradins Clinical University Hospital, Riga Stradiņš University, Riga, Latvia
,
Fares Moustafa
7   Department of Emergency, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
,
Javier Trujillo
8   Department of Internal Medicine, Hospital General Universitario Santa Lucía, Universidad Católica de Murcia, Murcia, Spain
,
Manuel Monreal
9   Department of Internal Medicine, Instituto de Salud Carlos III, Universidad Católica de Murcia, Hospital Germans Trias i Pujol, CIBERES, Badalona (Barcelona), Madrid, Spain
,
for the RIETE investigators › Author Affiliations

Abstract

The performance of validated bleeding risk scores in patients with venous thromboembolism (VTE) could be different depending on the time after index event or the site of bleeding. In this study we compared the “classic” Registro Informatizado de Enfermedad TromboEmbólica (RIETE) score and the more recently developed VTE-BLEED score for the prediction of major bleeding in patients under anticoagulant therapy in different time intervals after VTE diagnosis. Out of 82,239 patients with acute VTE, the proportion of high-risk patients according to the RIETE and VTE-BLEED scores was 7.1 and 62.3%, respectively. The performance of both scores across the different study periods (first 30 days after VTE diagnosis, days 31–90, days 91–180, and days 181–360) was similar, with areas under the receiving operating characteristics (ROC) curve (AUC) ranging between 0.69 and 0.72. However, the positive predictive values were low, ranging between 0.6 and 3.9 (better for early major bleeding than for later periods). A sensitivity analysis limited to patients with unprovoked VTE showed comparable results. Both scores showed a trend toward a better prediction of extracranial than intracranial major bleeding, the RIETE score resulting more useful for early extracranial bleeding and the VTE-BLEED for late intracranial hemorrhages. Our study reveals that the usefulness of available bleeding scores may vary depending on the characteristics of the patient population and the time frame evaluated. Dynamic scores could be more useful for this purpose.

Authors' Contribution

R.L., J.A.N., and M.M. were involved in study design, data collection and interpretation, writing and critical review, and final approval of the manuscript. L.J. was involved in data collection, data analysis and interpretation, writing and critical review, and final approval of the manuscript. All other authors were involved in data collection and interpretation, writing and critical review, and final approval of the manuscript.


* A full list of the RIETE investigators is given in the appendix.


Supplementary Material



Publication History

Received: 06 January 2021

Accepted: 16 March 2021

Article published online:
09 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
  • 2 Witt DM, Nieuwlaat R, Clark NP. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
  • 3 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
  • 4 Piovella C, Dalla Valle F, Trujillo-Santos J. et al; RIETE Investigators. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. Intern Emerg Med 2014; 9 (08) 847-852
  • 5 Klok FA, Niemann C, Dellas C, Hasenfuß G, Konstantinides S, Lankeit M. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 2016; 41 (02) 312-320
  • 6 Vedovati MC, Mancuso A, Pierpaoli L. et al. Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study. Int J Cardiol 2020; 301: 167-172
  • 7 Klok FA, Hösel V, Clemens A. et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48 (05) 1369-1376
  • 8 Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thromb Haemost 2017; 117 (06) 1164-1170
  • 9 Klok FA, Barco S, Turpie AGG. et al. Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. Br J Haematol 2018; 183 (03) 457-465
  • 10 Nishimoto Y, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry Group. Validation of the VTE-BLEED score's long-term performance for major bleeding in patients with venous thromboembolisms: from the COMMAND VTE registry. J Thromb Haemost 2020; 18 (03) 624-632
  • 11 Lecumberri R, Ruiz-Artacho P, Trujillo-Santos J. et al; RIETE Investigators. Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. Thromb Res 2020; 195: 139-145
  • 12 Nieto JA, Mora D, Bikdeli B. et al; RIETE Investigators. Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely. Thromb Res 2020; 189: 61-68
  • 13 Bikdeli B, Jimenez D, Hawkins M. et al; RIETE Investigators. Rationale, design and methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
  • 14 Ruíz-Giménez N, Suárez C, González R. et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (01) 26-31
  • 15 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 16 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148 (03) 839-843
  • 17 Jackson SL, Peterson GM, Vial JH, Jupe DM. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med 2004; 256 (02) 137-144
  • 18 Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. J Cardiovasc Pharmacol Ther 2015; 20 (05) 490-500
  • 19 Klok FA, Presles E, Tromeur C. et al; PADIS-PE Investigators. Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism. Res Pract Thromb Haemost 2019; 3 (03) 364-371
  • 20 Nieto JA, Camara T, Gonzalez-Higueras E. et al; RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (05) 789-796
  • 21 Klok FA, Barco S, Konstantinides SV. Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism. Eur Respir J 2018; 51 (04) 1800077
  • 22 Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 2012; 125 (11) 1095-1102
  • 23 Skowrońska M, Furdyna A, Ciurzyński M. et al. D-dimer levels enhance the discriminatory capacity of bleeding risk scores for predicting in-hospital bleeding events in acute pulmonary embolism. Eur J Intern Med 2019; 69: 8-13
  • 24 Kooiman J, van Hagen N, Iglesias Del Sol A. et al. The HAS-BLED Score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One 2015; 10 (04) e0122520
  • 25 Seiler E, Limacher A, Mean M. et al. Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. Thromb Haemost 2017; 117 (10) 1930-1936